Loading
A phase 2 trial of VS-7375, Cetuximab, Panitumumab in colorectal cancer, run by Verastem, Inc., now recruiting.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer is a phase 2 interventional study registered as NCT07659795 by Verastem, Inc., with 150 participants planned, started 2026-07-28 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares VS-7375, Verastem Oncology, Cetuximab.
Shares VS-7375, Verastem Oncology, Cetuximab, Colorectal cancer.
Shares VS-7375, Verastem Oncology.
Shares Panitumumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares Panitumumab, Cetuximab, Colorectal cancer.
Shares Panitumumab, Cetuximab, Colorectal cancer.
Shares Panitumumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/